Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Sees Significant Decline in Short Interest

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB – Get Free Report) saw a large drop in short interest during the month of June. As of June 30th, there was short interest totaling 6,105 shares, a drop of 70.1% from the June 15th total of 20,390 shares. Based on an average daily trading volume, of 64,461 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.1% of the shares of the company are short sold.

Matinas Biopharma Trading Down 27.1%

Shares of MTNB stock traded down $0.13 during trading hours on Tuesday, hitting $0.35. The company’s stock had a trading volume of 4,265,463 shares, compared to its average volume of 224,823. The company has a 50 day moving average of $0.68 and a 200 day moving average of $0.63. The stock has a market cap of $2.24 million, a PE ratio of -0.18 and a beta of 1.71. Matinas Biopharma has a 12-month low of $0.31 and a 12-month high of $3.09.

Get Matinas Biopharma alerts:

Matinas Biopharma (NYSEAMERICAN:MTNB – Get Free Report) last posted its earnings results on Friday, May 8th. The company reported ($0.30) earnings per share (EPS) for the quarter.

Institutional Trading of Matinas Biopharma

An institutional investor recently bought a new stake in Matinas Biopharma stock. DRW Securities LLC purchased a new stake in shares of Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB – Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned approximately 0.72% of Matinas Biopharma at the end of the most recent quarter. 11.77% of the stock is currently owned by institutional investors.

Matinas Biopharma Company Profile

(Get Free Report)

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.

Featured Stories

• Five stocks we like better than Matinas Biopharma
• Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet
• 3 Overlooked Energy ETFs Delivering Strong Returns and Income
• 3 Space Stocks That Could Outshine SpaceX After Its IPO
• JPMorgan’s Q2 Strength Gives the Stock Rally New Support

Receive News & Ratings for Matinas Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.